Consideration of gene therapy for paediatric neurotransmitter diseases
Authors:
- 3 March 2009
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 32 (3) , 387-394
Abstract
Summary: The paediatric neurotransmitter diseases (PNDs) are a group of inborn errors of metabolism characterized by abnormalities of neurotransmitter synthesis or metabolism. Although some children may react favourably to neurotransmitter augmentation treatment, optimal response is not universal and other modes of treatment should be sought. The genes involved in many of the currently known monoamine PNDs have been utilized in pre‐clinical and in phase I clinical trials in Parkinson disease (PD) and the basic principles could be applied to the therapy of PNDs with some modifications regarding the targeting and distribution of vectors. However, issues that go beyond neurotransmitter replacement are important considerations in PD and even more so in PNDs. Understanding the pathophysiology of PNDs including abnormal development resulting from the neurotransmitter deficiency will be critical for rational therapeutic approaches. Better animal models of PNDs are necessary to test gene therapy before clinical trials can be attempted.Keywords
Funding Information
- National Institutes of Health (R01NS32080)
This publication has 51 references indexed in Scilit:
- Towards gene therapy for Parkinson's diseaseThe Lancet Neurology, 2008
- Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagationNature Medicine, 2008
- Design of clinical trials of gene therapy in Parkinson diseaseExperimental Neurology, 2008
- Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicityBrain Research, 2008
- The Pediatric Neurotransmitter DisordersJournal of Child Neurology, 2007
- A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's diseaseAnnals of Neurology, 2003
- Thehph-1 mouse: A model for dominantly inherited GTP-cyclohydrolase deficiencyAnnals of Neurology, 2003
- Vesicular Monoamine Transporter-2 and Aromaticl-Amino Acid Decarboxylase Enhance Dopamine Delivery afterl-3,4-Dihydroxyphenylalanine Administration in Parkinsonian RatsJournal of Neuroscience, 1999
- Double Transduction with GTP Cyclohydrolase I and Tyrosine Hydroxylase Is Necessary for Spontaneous Synthesis ofl-DOPA by Primary FibroblastsJournal of Neuroscience, 1996
- Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal developmentNature, 1995